구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pegylated Liposomal Doxorubicin Hydrochloride (Pegylated Liposomal Doxorubicin Hydrochloride) AGO Research GmbH·Recurrent Platinum-Sensitive Fallo… 94 trials |
|---|---|
Overview Program | Pegylated Liposomal Doxorubicin Hydrochloride |
Overview Company | AGO Research GmbH |
Overview Modality | ADC |
Overview Target | Recurrent Platinum-Sensitive Fallopian T |
Overview Indication | Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.. Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery … |
Clinical Safety signal | Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.. Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery … |
Clinical Result source | ClinicalTrials.gov NCT02364713 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02364713 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | Pegylated Liposomal Doxorubicin Hydrochloride (Pegylated Liposomal Doxorubicin Hydrochloride) AGO Research GmbH·Recurrent Platinum-Sensitive Fallo… 94 trials |
|---|---|
Overview Program | Pegylated Liposomal Doxorubicin Hydrochloride |
Overview Company | AGO Research GmbH |
Overview Modality | ADC |
Overview Target | Recurrent Platinum-Sensitive Fallopian T |
Overview Indication | Fallopian Tube Carcinosarcoma; Fallopian Tube Clear Cell Adenocarcinoma |
Overview Phase | PHASE_2 |
Overview Status | DISCONTINUED |
Overview Content status | Limited Data |
Overview Data Confidence | Data Confidence · Low |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.. Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery … |
Clinical Safety signal | Taxane monotherapy regimens for the treatment of recurrent epithelial ovarian cancer.. Ovarian cancer is the seventh most frequent cancer diagnosis worldwide, and the eighth leading cause of cancer mortality. Epithelial ovarian cancer is the most common kind, accounting for 90% of cases. First-line therapy for women with epithelial ovarian cancer consists of a combination of cytoreductive surgery … |
Clinical Result source | ClinicalTrials.gov NCT02364713 |
Clinical Program phase | PHASE_2 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT02364713 |
추천 비교
추천 비교